According to Precedence Research, the global biologics CDMO market size will grow from USD 25.35 billion in 2025 to nearly USD 92.37 billion by 2034, with an expected CAGR of 15.45% from 2025 to 2034.

ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic(R) technology has been licensed by Ginkgo ...

Integrated analytical workflows are transforming cell line development by combining faster screening and streamlined decision-making.

Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...

Akebia filed its Investigational New Drug Application with the U.S. Food and Drug Administration (FDA) and recently initiated ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

MOG antibody-associated disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients ...

The PrIMAVeRa project develops a platform to evaluate how mAbs can combat AMR by reducing antibiotic use and providing ...

A new artificial intelligence model could help design antibodies that better protect the body against viruses and disease.

During this unique study, scientists sought to understand if artificial intelligence could be used to predict how the ...

Since its introduction in the late 1980s, HIV antiretroviral therapy (ART) has saved millions of lives by transforming HIV from a fatal disease into a chronic, manageable condition. Despite these ...